Tripep and Kringle Pharma applies cooperatively for permission to launch a Phase II study of ChronSeal

Tripep and Kringle Pharma applies cooperatively for permission to launch a Phase
II study of ChronSeal

Tripep has submitted an application to the Medical Products Agency concerning
the initiation of a Phase II study of ChronSeal, a product owned jointly by
Tripep and Kringle Pharma for the treatment of chronic leg wounds. The study,
which will take the form of a placebo controlled multicenter study, will be
implemented in Sweden and comprise 60 patients. If approval is granted, it is
estimated that the study will start during the first half of 2008.

ChronSeal is a HGF-based (Hepatocyte Growth Factor) treatment for chronic leg
wounds, a rapidly increasing problem among the elderly population of the Western
World. In cooperation with Tripep's partners Kringle Pharma and Zelmic AB, a new
formulation has been developed that enables the use of ChronSeal without it
being combined with antibiotics. The new formulation allows for controllable
release of HGF, while avoiding antibiotic resistance, another rapidly growing
problem. An application for a patent pertaining to an antibiotic-free
formulation of ChronSeal was filed in the US earlier this month. "Two clinical pilot studies comprising a total of 24 patients have been
conducted, which showed that those patients who received active treatment
attained 60% wound healing after one week. Thanks to these excellent treatment
results, we have great expectations concerning the imminent Phase II study based
on the new, antibiotic-free formulation," says Jan Nilsson, CEO of Tripep."Kringle and Tripep have been working closely together for a year and this is a
significant milestone for both companies," says Kunio Iwatani, CEO of Kringle
Pharma. "We maintain and strengthen good relations with each other to meet the
requirements necessary to bring this HGF-based novel therapy to the market."

More than four million people in the US and Europe are currently suffering from
chronic leg wounds. This corresponds to a market value of approximately SEK12
billion. Accordingly, the medical need is considerable and the growth rate is
high, factors that are expected to provide ChronSeal with substantial commercial
potential. 



For more information, please contact:

Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63
E-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se


About Tripep AB
Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB.  For more information, please refer to the
company's Website: www.tripep.se .
About Kringle Pharma, Inc. 
Kringle Pharma is a biopharmaceutical company established in 2001 to develop
novel biologics based on HGF and NK4, both discovered by Professor Toshikazu
Nakamura at Osaka University. Currently, Kringle's pipeline consists of human
recombinant HGF for the treatment of 1) acute renal failure, 2) skin ulcers, and
3) CNS diseases, in addition to human recombinant NK4 and NK4 gene drug for
cancer therapies. For more information, please refer to the company's website:
www.kringle-pharma.com/en/index.html .